Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2020 22:00 ET | Source: Hookipa Pharma Inc

HOOKIPA Pharma Announces Pricing of Public Offering of Common Stock and Preferred Stock

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
December 08, 2020 16:01 ET | Source: Hookipa Pharma Inc

HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Preferred Stock

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
December 07, 2020 06:00 ET | Source: Hookipa Pharma Inc

HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability

Results support first proof of concept for HOOKIPA’s replicating investigational single-vector immunotherapy in oncologyData demonstrate responses and stable disease in some head and neck cancer...
November 30, 2020 06:00 ET | Source: Hookipa Pharma Inc

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV...
November 12, 2020 07:15 ET | Source: Hookipa Pharma Inc

HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
November 11, 2020 07:00 ET | Source: Hookipa Pharma Inc

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

NEW YORK and VIENNA, Austria, Nov. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
November 03, 2020 07:00 ET | Source: Hookipa Pharma Inc

HOOKIPA Pharma To Report Third Quarter 2020 Financial Results on November 12, 2020

NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
October 29, 2020 07:30 ET | Source: Hookipa Pharma Inc

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers

- HB-202/HB-201 alternating two-vector therapy is added as an additional arm that expands the ongoing HB-201 clinical trial - Pre-clinical data show that adding an additional arenaviral vector to...
October 19, 2020 08:00 ET | Source: Hookipa Pharma Inc

HOOKIPA Appoints Prof. Jean-Charles Soria, Director General of the Gustave Roussy Cancer Center in Paris, to its Board of Directors

NEW YORK and VIENNA, Austria, Oct. 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers...
September 16, 2020 07:45 ET | Source: Hookipa Pharma Inc

HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

Peer reviewed article in OncoImmunology demonstrates promising preclinical results for the novel cancer therapy targeting Human Papillomavirus 16 (HPV16) E6/E7 HPV is estimated to cause...